Project description DEENESFRITPL Cancer chemotherapy during pregnancy and DNA damage in the offspring Cancer during pregnancy represents an important health challenge affecting both mother and child. Previous clinical studies have shown that chemotherapy during pregnancy is relatively safe for infants in the short term, but children born after in utero exposure to chemotherapy are often smaller for their gestation age and have lower IQs, suggesting possible long-term health effects. The EU-funded SCAR project will study epigenetic modifications in umbilical cord blood cells of exposed children to determine whether in utero exposure to carboplatin chemotherapy may be linked to DNA damage in the offspring. The studying of the underlying molecular epigenetic changes at birth will provide immediate evidence and will be instrumental in defining safe and solid treatment guidelines for pregnant cancer patients. Show the project objective Hide the project objective Objective Cancer complicates 1 in 1000 pregnancies representing an important health challenge that affects both mother and child. In a series of breakthrough clinical studies, the hosting lab has shown that chemotherapy given during pregnancy is relatively safe for the infants in the short term. However, children born after in utero exposure to chemotherapy are often small for their gestation age, present with lower IQ scores and have higher risk to wear glasses, suggesting possible long-term health effects. Because chemotherapy elicits (epi)genetic alterations to cancer patients, we hypothesize that chemotherapy-mediated long-term health effects could be due to (epi)genetic changes in the offspring of women treated with chemotherapy during pregnancy. Thus, SCAR aims to determine whether in utero exposure to carboplatin may be linked to DNA damage in the offspring. My objectives are to 1) identify the genetic damage at single cell level and 2) determine epigenetic modifications; in umbilical cord blood cells of children in utero exposed to carboplatin. To this end, I will integrate highly innovative sequencing techniques and the access of the hosting team to a unique registry of pregnant cancer patients. As the phenotypic expression of these genetic alterations could take decades to appear, studying the underlying molecular epi(genetic) changes at birth, will provide more immediate evidence than long-term clinical follow-up, and will be instrumental to define safe and solid treatment guidelines for pregnant cancer patients. Through this work, I aim to broaden my scientific expertise (including technical and transferable skills) and my international network for pursuing an academic career in Europe. The MSCA-IF will be instrumental to actualize many objectives outlined in my career development plan in order to become an independent researcher in the genetic oncology field. Fields of science natural sciencesbiological sciencesgeneticsDNAengineering and technologymaterials engineeringmedical and health sciencesclinical medicineobstetricsmedical and health sciencesclinical medicineoncologynatural sciencesbiological sciencesgeneticsepigenetics Keywords Oncology Genetics Breast cancer chemotherapy epigenetics Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2019 - Individual Fellowships Call for proposal H2020-MSCA-IF-2019 See other projects for this call Funding Scheme MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF) Coordinator KATHOLIEKE UNIVERSITEIT LEUVEN Net EU contribution € 178 320,00 Address OUDE MARKT 13 3000 Leuven Belgium See on map Region Vlaams Gewest Prov. Vlaams-Brabant Arr. Leuven Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 178 320,00